HSV therapy (Rega)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameHSV therapy (Rega)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThymidine kinase inhibitors
TargetsThymidine kinase
Therapy Area/IndicationsHerpes Simplex Virus Type 2 InfectionsHerpes Simplex Virus Type 1 Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRega Institute for Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRega Institute for Medical ResearchKing'S College London
Active IndicationsN/A
Inactive IndicationsHerpes Simplex Virus Type 2 InfectionsHerpes Simplex Virus Type 1 Infections

Other Information

ATC CodeN/A
Related LinksN/A